Debora De Melo Gagliato

Adma Jafet St 91
Sao Paulo, SP, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study.

Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study.

Journal: Breast (Edinburgh, Scotland)

Published: May 04, 2025

Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 study.

Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 study.

Journal: Breast (Edinburgh, Scotland)

Published: January 15, 2025

Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study.

Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study.

Journal: Therapeutic advances in medical oncology

Published: September 21, 2022

Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges.

Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: September 02, 2020

CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge.

CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge.

Journal: Cancers

Published: July 08, 2020

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.

Journal: Cancer cell

Published: April 06, 2020

Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer.

Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer.

Journal: The oncologist

Published: September 28, 2019

Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds.

Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds.

Journal: Oncoimmunology

Published: September 01, 2019

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology.

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology.

Journal: Integrative cancer therapies

Published: September 20, 2018

Noninvasive cancer biomarkers in solid malignancies: circulating tumor DNA-clinical utility, current limitations and future perspectives.

Noninvasive cancer biomarkers in solid malignancies: circulating tumor DNA-clinical utility, current limitations and future perspectives.

Journal: Annals of translational medicine

Published: July 20, 2018

Delays in Adjuvant Chemotherapy Among Breast Cancer Patients: An Unintended Consequence of Breast Surgery?

Delays in Adjuvant Chemotherapy Among Breast Cancer Patients: An Unintended Consequence of Breast Surgery?

Journal: Annals of surgical oncology

Published: February 07, 2018

Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors.

Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 21, 2017

Showing 1-12 of 22

Last Updated: 09/26/2026